The file room
Every story on file, newest first. Filter by bay, region or how far a plant has got.
11 of 33 stories · sheet 1 of 2
B2Process
Daewon Pharmaceutical says its oral semaglutide candidate reached up to 3.14 times the exposure of Rybelsus in two crossover studies. The data are unpublished, and the company has not named a peptide supplier.
B4Deals
Gilead will pay $1.275 billion in upfront cash for PepStar's oral macrocyclic peptide program, led by Phase 1 candidate HCXT-2001. The deal brings worldwide rights but no site, supplier or capacity.
B2Process
Dr. Reddy's holds generic semaglutide approvals in ten countries, but pen supply stopped in July when a scaled up ingredient batch produced an impurity in the finished drug. A November relaunch depends on validation.
B1Plants
Premium International Injectable has finished an insulin plant in the Koggala Export Processing Zone, a joint venture with Sri Lanka's state drug maker backed by a 15 year supply deal. Validation comes first, with output expected in 2027.
B1Plants
QL Biopharm signed with the Wuxi city government on October 21 to build a research and production base for its monthly GLP 1 injection and oral peptide. The company uses E. coli expression, but gave no budget, capacity or start date.
B4Deals
Shenzhen Hybio forecasts nine month profit up more than fivefold on active ingredient sales, now four fifths of revenue. A planned RMB 968 million share placement to expand peptide lines expired on October 12.
B4Deals
Holders of 87.88% of PolyPeptide shares accepted the Korean group's cash offer, but clearances and a board vote remain. A 350.8 billion won European order shows the core business still filling up.
B3Trade
Chengdu Shengnuo Biopharm and Nanjing Chengong Pharmaceutical were added to FDA's red list for all drug products, after inspections reported mould, insects and unchecked outside ingredient.
